The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 3×
“Ampli®cation/overexpression of HER2, especially, has been associated with a poor patient prognosis (Slamon et al., 1987, 1989).”
BackgroundDiscovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“In the HER2/3 heterodimer, HER3, which exhibits reduced intrinsic catalytic activity (Guy et al., 1994) appears to provide ligand binding activity and the ability to associate with PI-3 kinase, while HER2 contributes kinase activity and the ability to phosphorylate downstream substrates (Carraway…”
BackgroundBiscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Self-citationMaa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C., & Parsons, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6981 · Cited by 330
Self-citation
Research works printed but not linked: 49
- Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ . 1999 Oncogene 18: 6050–6062 · DOI
- Alroy I, Yarden Y . 1997 FEBS Lett. 410: 83–86 · DOI · Paper page
- Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, Bishop PR, Damstrup L, Coffey RJ . 1994 J. Biol. Chem. 269: 22817–22822 · DOI · Paper page
- Belsches AP, Haskell MD, Parsons SJ . 1997 Frontiers in Biosc. 2: 501–518 · DOI
- Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RCJ . 1990 Cancer Res. 50: 4087–4091
- Biscardi JS, Belsches AP, Parsons SJ . 1998 Mol. Carcinog. 21: 261–272 · DOI · Paper page
- Biscardi JS, Tice DA, Parsons SJ . 1999b Adv. In Cancer Res. 76: 61–119 · DOI · Paper page
- Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ . 2000 Breast Cancer Res. 2: 203–210 · DOI · Paper page
- Campbell DH, deFazio A, Sutherland RL, Daly RJ . 1996 Int. J. Cancer 68: 485–492 · doi:10.1002/(sici)1097-0215(19961115)68:4<485::aid-ijc14>3.0.co;2-4
- Carraway III KL, Soltoff SP, Diamonti AJ, Cantley LC . 1995 J. Biol. Chem. 270: 7111–7116 · DOI
- Carraway III KL, Cantley LC . 1994 Cell 78: 5–8 · DOI · Paper page
- Crovello CS, Lai C, Cantley LC, Carraway III KL . 1998 J. Biol. Chem. 273: 26954–26961 · DOI
- Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ . 1997 Mol. Cell Biol. 17: 5410–5425 · DOI
- De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ . 1990 Int. J. Cancer 45: 55–58 · doi:10.1002/ijc.2910450112
- DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA . 1987 Science 237: 178–182 · DOI · Paper page
- Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ . 1998 J. Biol. Chem. 273: 7717–7724 · DOI
- Gamett DC, Greene T, Wagreich AR, Kim HH, Koland JG, Cerione RA . 1995 J. Biol. Chem. 270: 19022–19027 · DOI
- Guy CT, Webster MA, Schaller M, Parson TJ, Cardiff RD, Muller WJ . 1992 Proc. Natl. Acad. Sci. USA 89: 10578–10582 · DOI · Paper page
- Hynes NE, Stern DR . 1994 Biochim. Biophys. Acta 1198: 165–184 · DOI · Paper page
- Karni R, Jove R, Levitzki A . 1999 Oncogene 18: 4654–4662 · DOI · Paper page
- Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y . 1996 EMBO J. 15: 254–264 · DOI · Paper page
- Kaspers GJL, Pieters R, Van Zantwijk CH, De Laat PAJM, De Waal FC, Van Wering ER, Veerman AJP . 1991 Br. J. Can. 64: 469–474 · doi:10.1038/bjc.1991.333
- Komurasaki T, Toyoda H, Uchida D, Morimoto S . 1997 Oncogene 15: 2841–2848 · DOI
- Linsley PS, Fox CF . 1980 J. Supramol. Struct. 14: 441–459 · DOI
- Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez J, Berman J, Gilmer TM . 1994 Proc. Natl. Acad. Sci. USA 91: 83–87 · DOI · Paper page
- Maguire Jr HC, Hellman ME, Greene MI, Yeh I . 1992 Pathobiology 60: 117–121 · doi:10.1159/000163709
- Malik RK, Parsons JT . 1996 Biochim. Biophys. Acta. 1287: 73–76 · DOI
- Massague J . 1983 J. Biol. Chem. 258: 13614–13620 · DOI · Paper page
- Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ . 1994 Mol. Cell Biol. 14: 735–743 · DOI · Paper page
- Muthuswamy SK, Muller WJ . 1995 Oncogene 11: 271–279 · DOI
- Parsons SJ, McCarley DJ, Ely CM, Benjamin DC, Parsons JT . 1984 J. Virology 51: 272–282 · DOI
- Parsons SJ, McCarley DJ, Raymond VW, Parsons JT . 1986 J. Virology 59: 755–758 · DOI
- Parsons JT, Parsons SJ . 1997 Curr. Op. Cell Biol. 9: 187–192 · DOI · Paper page
- Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y . 1996 EMBO J 15: 2452–2467 · DOI · Paper page
- Pinkas-Kramarski R, Shelly M, Guarino CB, Wang LM, Lyass L, Alroy I, Alamandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y . 1998 Mol. Cell Biol. 18: 6090–6101 · DOI
- Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA . 1990 J. Pathol. 161: 7–14 · DOI
- Riese DJ II, Komurasaki T, Plowman GD, Stern DF . 1998 J. Biol. Chem. 273: 11288–11294 · DOI
- Roche S, Koegl M, Barone MV, Roussel MF, Courtneidge SA . 1995 Mol. Cell Biol. 15: 1102–1109 · DOI · Paper page
- Sato K-I, Sato A, Aoto M, Fukami Y . 1995 Biochem. Biophys. Res. Commun. 210: 844–851 · DOI
- Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang L-M, Lyass L, Alimandi M, Kuo A, Bacus S, Pierce JH, Andrews GC, Yarden Y . 1998 J. Biol. Chem. 273: 10496–10505 · DOI · Paper page
- Sierke SL, Longo GM, Koland JG . 1993 Biochem. Biophys. Res. Commun. 191: 45–54 · DOI
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF . 1989 Science 244: 707–712 · DOI · Paper page
- Soltoff SP, Carraway KL, Prigent SA, Gullick WG, Cantley LC . 1994 Mol. Cell Biol. 14: 3550–3558 · DOI · Paper page
- Tice DA, Biscardi JS, Nickles AL, Parsons SJ . 1999 Proc. Natl. Acad. Sci. USA 96: 1415–1420 · DOI · Paper page
- Toi M, Osaki A, Yamada J, Toge T . 1991 Eur. J. Cancer 27: 977–980 · DOI
- Villaneuva A, Stockert JC, Armas-Portela R . 1984 Histochem. 81: 103–104 · doi:10.1007/bf00495409
- Wallasch C, Weiss FU, Niederfellnew G, Jallal B, Issing W, Ullrich A . 1995 EMBO J. 14: 4267–4275 · DOI · Paper page
- Ware JL, Maygarden SJ, Koontz WW, Strom SC . 1991 Hum. Pathol. 22: 254–258 · doi:10.1016/0046-8177(91)90159-m
- Wilson LK, Luttrell DK, Parsons JT, Parsons SJ . 1989 Mol. Cell Biol. 9: 1536–1544 · DOI
Cited by
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“…tyrosine phosphorylation (Figure 2B). increasing the translocation of PTEN from the cytoplasm to the membrane through reducing the inhibitory tyrosine phosphory-Src is known to bind to ErbB2 and is thus activated in ErbB2-overexpressing cancer cells (Belsches-Jablonski et al., 2001; lation of PTEN.”
BackgroundMoasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,219
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
c-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617
Self-citationZhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
The interplay between Src family kinases and receptor tyrosine kinases
Bromann, P. A., Korkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 454
p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2
Chu, I., Sun, J., Arnaout, A., Kahn, H., Hanna, W., Narod, S., Sun, P., Tan, C.-K., Hengst, L., & Slingerland, J. (2007) · Cell · doi:10.1016/j.cell.2006.11.049 · Cited by 372
Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents
Ren, J., Agata, N., Chen, D., Li, Y., Yu, W.-H., Huang, L., Raina, D., Chen, W., Kharbanda, S., & Kufe, D. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00020-0 · Cited by 325
Henson, E. S., & Gibson, S. B. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.05.015 · Cited by 300
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
Liang, K., Esteva, F. J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.-Y., Li, Y., Li, X., Chen, C.-T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.025 · Cited by 139
Rexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“Investigations into the molecular interactions between SFKs and EGFR have revealed that SFKs can physically associate with activated EGFR (Belsches-Jablonski et al., 2001; Maa et al., 1995; Muthuswamy and Muller, 1995).”
BackgroundSrc continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111
Zheng, X., Resnick, R. J., & Shalloway, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23321 · Cited by 60
“One possibility is activation via members of the human epidermal growth factor receptor (EGFR/HER) family, which are overexpressed in a majority of human breast cancer tissues and cell lines.(5) Src associates with HER1 and HER2(6) and can be activated by these proteins in human breast and colon cancer cells and in a…”
BackgroundCombined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo
Chen, Y., Alvarez, E. A., Azzam, D., Wander, S. A., Guggisberg, N., Jordà, M., Ju, Z., Hennessy, B. T., & Slingerland, J. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1024-7 · Cited by 54
Metadata
- Authors
- Belsches-Jablonski, A. P., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J.
- Venue
- Oncogene
- Published
- 2001-03-22
- Volume
- 20
- Issue
- 12
- Pages
- 1465-1475
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2037297522
- Cited by
- 185
- References
- 5
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.